



FEE TRANSMITTAL for FY 2004

Effective 10/01/2003, Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 55.00)

Complete if Known

Application Number	09/844,281
Filing Date	April 30, 2001
First Named Inventor	B.L. Mangold et al.
Examiner Name	Jennifer E. Graser
Group Art Unit	1645
New Attorney Docket No.	54461-20001.00

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order Other None

Deposit Account:

Deposit Account Number 03-1952

Deposit Account Name Morrison & Foerster LLP

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments

Charge any additional fee(s) or any underpayment of fee(s)

Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	55
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	
Other fee (specify)		12 Advance Copies of Patent			

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 55.00)

** or number previously paid, if greater; For Reissues, see above

SUBMITTED BY: Morrison & Foerster LLP

Name (Print/Type)	By: James Remenick	Registration No. (Attorney/Agent)	36,902	Telephone	(703) 760-7700
Signature				Date	August 16, 2004



1645
JRW

New Attorney Docket No. 54461-20001.00
Old Attorney Docket No. 38602.0003
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Beverly L. Mangold et al.

Application No.: 09/844,281

Group Art Unit: 1645

Filed: April 30, 2001

Examiner: Jennifer E. Graser

Title: ANTHRAX SPECIFIC ANTIBODIES

Mail Stop: Amendment

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

a.) Introductory Remarks

AMENDMENT AND RESPONSE TO NON-FINAL OFFICE ACTION

This is in response to the non-final Office Action, mail dated April 14, 2004 (Paper No. 20040407), for which a response was due on July 14, 2004. Filed herewith is a Petition and fee for a one month(s) extension of time, thereby extending the deadline for response to August 16, 2004 (August 14th was a Saturday). Accordingly, this response is timely filed. Reconsideration and allowance of the pending claims, as amended, in light of the remarks presented herein are respectfully requested.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper. **Remarks** begin on page 7 of this paper.

08/17/2004 GNDRDOF1 00000060 031952 09844281

01 FC:2251 55.00 DA